|British American Tobacco
||EPS - Basic
||Market Cap (m)
British American Tobacco Share Discussion Threads
Showing 2251 to 2272 of 2275 messages
|'British American Tobacco Set to Light It Up'
|Interesting article from the SeekingAlpha website:
'British American Tobacco said demand for its "glo" device overwhelmed supply in its Japan test marketing as global cigarette giants shift focus to the "heat but not burn" category amid declining smoking population. Philip Morris (NYSE:PM) announced earlier this month that it had more than doubled the supply of its IQOS tobacco device but it was still not enough to cover demand. BTI +1.1% premarket.'
And as I posted a short while ago £50, once broken up through, will become a solid support level going forward: it's yet to be tested, and maybe even £51 will hold. This is a good share to buy and hold: the dividend gives better returns than a deposit account, and as long as one doesn't commit capital that will be needed in the short to medium term, your deposit increases too, courtesy of capital growth in the share price.
Buy or buy more, especially if £50 does get tested for any reason.|
|BAT says strong demand for 'glo' smokeless tobacco
|Doing well today. Taking into account the dividend stripped out we're +70p on the day so far.|
|XD tomorrow morning for the 118p dividend|
|Menthol cigarettes to be phased out within weeks ahead of complete ban
The ban also includes skinny 'lipstick-style' cigarettes and flavours such as vanilla and strawberry
|Eyewitness NewsVerified account @ewnupdates 14 hours ago
[LISTEN] British American Tobacco clarifies issue of SA plant closure
|Argus upgraded British American Tobacco (NYSE: BTI) from Hold to Buy with a price target of $72.00.
Analyst David Coleman comments "A leading global tobacco supplier, British American has a record of consistent growth, with strong gains in revenue, net income, and adjusted EPS over the last five and a half years.
The company also has a 42% stake in U.S.-based Reynolds American (RAI), and plans to acquire the remaining 57.8% of Reynolds that it does not already own. The acquisition, which is expected to close in 3Q17, will increase BTI's exposure to high-growth emerging markets while also strengthening its presence in the U.S.
It will also help BTI to expand its R&D program, which is focused on the of e-cigarettes and other smokeless products, and to boost its share of the smokeless market. Management plans to quadruple the number of markets in which it offers e-cigarettes and other smokeless products by 2018.
We believe the near-term outlook for British American has improved and see further upside for the shares."
|Thanks for the reply and the the chart...I'm in both and bhp has been fantastic....BAT'S divi's actually closes that gap a lot.|
|A minimum excise tax on cigarettes will hurt lower earners and fuel the black market, British American Tobacco says
|'British American Tobacco chief confident of ecigarette push'
Nicandro Durante shrugs off suggestions it is playing catch-up in fast-growing market
|27th feb Jefferies buy tp 5800p
|BAT ‘particularly well placed’ in 2017, says Jefferies
Annual results from British American Tobacco (BATS) showed better-than-expected profit margins and Jefferies believes it is one of the best placed tobacco companies.
Analyst Owen Bennett retained his ‘buy’ recommendation and price target of £58 after full-year results showed the maker of Dunhill and Lucky Strike cigarettes lifted adjusted profits by 9.8% to £5.48 billion last year. The shares gained 60p on Thursday to close 1.2% higher at £50.60.
‘We continue to see BAT as particularly well placed as a standalone company with expected full-year 2016-full year 2020 earnings per share growth of over 11%,’ he said.
‘In addition to supportive FX [foreign exchange currency movements], strong organic development is driven by the most attractive market share outlook across the space, among the international names, and a continuing self-help story for a number of years yet.’
Bennett said the $49.4 billion acquisition of Reynolds American should ‘add to the already strong growth profile’ by reducing its exposure to the slowdown in emerging markets while improving its competitive position in cleaner ‘vapour’ tobacco products, where arch-rival Philip Morris has taken a lead with its IQOS tobacco heating device.
|Yep, solid numbers :-)
'Reynolds American Downgraded at Wells Fargo, But Firm Sees BAT Deal Closing'
|Nice 10% dividend hike in the results.HTTP://www.investegate.co.uk/british-am--tobacco--bats-/rns/final-results/201702230700116106X/|
|British American Tobacco sets sight on dominance in alternative products
|Results out on Thursday.|
|Great thanks. Need to form a base camp above £50.|
|14th feb Citigroup buy tp 5600p
BAT is now very well positioned to take advantage of the potential growth of the Next Generation Products (NGPs). When combined with Reynolds American, BAT has, through a mixture of acquisitions and its own investments, become market leader in vaping in the US, UK and Poland but also with a presence in most key western European markets.
In December 2016 the group launched its heated tobacco product in the city of Sendai in Japan, and it has a hybrid called iFUSE in the Romanian market. On the vaping side BAT has a portfolio of open and closed system products, the ability to develop and produce
its own e-liquids and more recently developed a new convenient format called epebble. Furthermore, in 2017 it will be looking to launch a vaping product called ‘Raptor’ that is said to allow a more rapid nicotine absorption by consumers than historical products.
2017 is likely to be the year that PMI’s iQOS makes significant volume gains but it is clear that BAT has a very competitive portfolio across all existing products, though how successful or otherwise will not become clear until 2018. It is worth pointing out that BAT will be able to market its full range of products in the important US market, where the tobacco market leader, Altria Group, has only made selective investments in vaping and will be the license holder for iQOS when this is launched post-approval by the FDA, probably in 2018.
Following the consolidation of Reynolds American the group will generate over 40% of its net profits from the US market and c63% of profits from the developed world. Historically, BAT had a strong bias towards the emerging markets (EM) but this has now changed. We believe this points to both how attractive management views the US market following the 2015 acquisition of Lorillard by Reynolds American, but also possibly that some of the major challenges of volume declines and offsetting rising costs will be felt primarily in the EM.
BAT stated it estimates potential cost synergies of around $400m but without mentioning a timeframe. Based on 2016 estimates this would represent 2.2% of the combined cost base, excluding Medicaid Settlement (MSA) and FDA payments.
Given the lack of geographic overlap the low rate of cost savings is hardly surprising; moreover the savings would represent an impressive 11% of the estimated 2016 cost base (excluding MSA and FDA payments) of Reynolds American as a standalone business. Clearly BAT could be a major beneficiary of any moves to reduce the US corporate tax rate, but our current estimates assume no change.
We increase our price target by 10% to 5,670p and upgrade the rating from Hold to Buy. The price target reflects the change in the DCF valuation based on the estimates for the combined group.
|Berenberg upgrading from 'hold' to 'buy' .... tp up from 5150p to 5670p|
|British American Tobacco to Discontinue Dunhill Cigars and Pipe Tobacco